New study tracks gene mutations in breast cancer patients on alpelisib
NCT ID NCT05022342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study in India enrolled 595 people with HR-positive, HER2-negative advanced or metastatic breast cancer who were already taking alpelisib plus fulvestrant. Researchers looked for PIK3CA gene mutations in tumors and tracked how well the cancer responded to treatment. The goal was to better understand the link between these mutations and patient outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alpelisib plus fulvestrant
What this could lead to
If successful, this could help doctors understand which patients with advanced breast cancer might benefit most from alpelisib treatment.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500034, India
-
Novartis Investigative Site
Guwahati, Assam, 781023, India
-
Novartis Investigative Site
Kochi, Kerala, 682041, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400071, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 441108, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110092, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751007, India
-
Novartis Investigative Site
Chandigarh, Punjab, 160055, India
-
Novartis Investigative Site
Ludhiana, Punjab, 141008, India
-
Novartis Investigative Site
Jaipur, Rajasthan, 302017, India
-
Novartis Investigative Site
Sherilingampally, Telangana, 500019, India
-
Novartis Investigative Site
Howrah, West Bengal, 711103, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700029, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700054, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700063, India
-
Novartis Investigative Site
Ahmedabad, 380054, India
-
Novartis Investigative Site
Kanpur, 208002, India
-
Novartis Investigative Site
Kolkata, 700016, India
-
Novartis Investigative Site
Kolkata, 700026, India
-
Novartis Investigative Site
Kolkata, 700107, India
-
Novartis Investigative Site
Puducherry, 605006, India
-
Novartis Investigative Site
Udaipur, 313011, India